Integra LifeSciences (IART - Free Report) reported $397.04 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 0.3%. EPS of $0.89 for the same period compares to $0.94 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $398.81 million, representing a surprise of -0.44%. The company delivered an EPS surprise of -1.11%, with the consensus EPS estimate being $0.90.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Revenue Growth: -1.2% compared to the 0% average estimate based on two analysts.
- Revenue- Codman Specialty Surgical- Total: $271.63 million compared to the $281.64 million average estimate based on six analysts. The reported number represents a change of +2.7% year over year.
- Revenue- Tissue Technologies- Total: $125.41 million versus the six-analyst average estimate of $117.18 million. The reported number represents a year-over-year change of -6%.
- Revenue- Tissue Technologies- Private Label: $31.55 million compared to the $24.79 million average estimate based on four analysts. The reported number represents a change of +2.2% year over year.
- Revenue- Codman Specialty Surgical- Instruments: $61.42 million versus the four-analyst average estimate of $64.33 million. The reported number represents a year-over-year change of +3.4%.
- Revenue- Codman Specialty Surgical- Neurosurgery: $210.20 million compared to the $216.95 million average estimate based on four analysts. The reported number represents a change of +2.4% year over year.
- Revenue- Tissue Technologies- Wound Reconstruction and Care: $93.86 million versus the four-analyst average estimate of $93.18 million. The reported number represents a year-over-year change of -8.5%.
View all Key Company Metrics for Integra here>>>Shares of Integra have returned +8.3% over the past month versus the Zacks S&P 500 composite's +4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Integra LifeSciences (IART - Free Report) reported $397.04 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 0.3%. EPS of $0.89 for the same period compares to $0.94 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $398.81 million, representing a surprise of -0.44%. The company delivered an EPS surprise of -1.11%, with the consensus EPS estimate being $0.90.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Revenue Growth: -1.2% compared to the 0% average estimate based on two analysts.
- Revenue- Codman Specialty Surgical- Total: $271.63 million compared to the $281.64 million average estimate based on six analysts. The reported number represents a change of +2.7% year over year.
- Revenue- Tissue Technologies- Total: $125.41 million versus the six-analyst average estimate of $117.18 million. The reported number represents a year-over-year change of -6%.
- Revenue- Tissue Technologies- Private Label: $31.55 million compared to the $24.79 million average estimate based on four analysts. The reported number represents a change of +2.2% year over year.
- Revenue- Codman Specialty Surgical- Instruments: $61.42 million versus the four-analyst average estimate of $64.33 million. The reported number represents a year-over-year change of +3.4%.
- Revenue- Codman Specialty Surgical- Neurosurgery: $210.20 million compared to the $216.95 million average estimate based on four analysts. The reported number represents a change of +2.4% year over year.
- Revenue- Tissue Technologies- Wound Reconstruction and Care: $93.86 million versus the four-analyst average estimate of $93.18 million. The reported number represents a year-over-year change of -8.5%.
View all Key Company Metrics for Integra here>>>Shares of Integra have returned +8.3% over the past month versus the Zacks S&P 500 composite's +4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on IART - FREE